Dolutegravir population pharmacokinetics in racially, sex- and age-diverse and antiretroviral therapy-experienced adults with HIV in the United States

By afschroeder • July 18, 2026

Khoei A, Edmonds A, Chang Y, Ramirez C, Vogan M, Poliseno A, Wolinsky S, Ho K, Brown TT, Margolick JB, Batson J, Hoffmann J, Marzinke MA, Kempf MC, Alcaide ML, Effoe J, Lahiri CD, Ofotokun I, Sheth AN, Gange S, French AL, Tamraz B, Aouizerat BE, Tien PC, Kassaye SG, DeHovitz J, Anastos K, Chew KW, Floris-Moore M, Dumond JB. Dolutegravir population pharmacokinetics in racially, sex- and age-diverse and antiretroviral therapy-experienced adults with HIV in the United States. HIV Med. 2026 Jul 17. doi: 10.1111/hiv.70278. Epub ahead of print. PMID: 42466959.

Tags: clinical pharmacology, dolutegravir pharmacokinetics, Infectious Diseases, integrase inhibitor, men with HIV, population pharmacokinetics, Publications, women with HIV

Integrating long-acting injectable cabotegravir for HIV prevention into the Brazilian public health system ImPrEP CAB Brasil: a hybrid type-2 implementation-effectiveness cohort study

Grinsztejn B, Torres TS, Hoagland B, Coutinho C, Silva MST, Leite IC, Cunha M, Derrico M, Jalil EM, Cardoso SW, Trefiglio R, Farias A, Mourão[...]

Diagnostics for Hemorrhagic Fever Viruses: Lassa Fever as an Example

Dhar B, Espinoza N, Farzani T, Baudi I, Nosamiefan D, Garcia CY, Allan-Blitz LT, Samani P, Happi C, Sabeti P. Diagnostics for Hemorrhagic Fever Viruses:[...]

Transferrin Enhances Antifungal Therapy and Improves Survival in Experimental Mucormycosis

Gu Y, Gebremariam T, Ibrahim BA, Harb K, Chan A, Ibrahim AS. Transferrin Enhances Antifungal Therapy and Improves Survival in Experimental Mucormycosis. J Fungi (Basel).[...]